Research programme: lysosomal storage disease therapeutics - NanoMedSyn

Drug Profile

Research programme: lysosomal storage disease therapeutics - NanoMedSyn

Alternative Names: recombinant acid alpha-glucosidase conjugated with AMFA; Recombinant human acid alpha-glucosidase conjugated with mannose-6-phosphate analogues

Latest Information Update: 05 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator NanoMedSyn
  • Class Enzymes
  • Mechanism of Action Alpha glucosidase replacements; Enzyme replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glycogen storage disease type II
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Glycogen storage disease type II; Lysosomal-storage diseases

Most Recent Events

  • 26 Mar 2018 NanoMedSyn and Shire enter a research collaboration to develop lysosomal storage disease therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top